- Home
- CDLR vs GLPG Comparison
CDLR vs GLPG Comparison
Compare CDLR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLR
- GLPG
- Stock Information
- Founded
- CDLR 2008
- GLPG 1999
- Country
- CDLR Denmark
- GLPG Belgium
- Employees
- CDLR N/A
- GLPG N/A
- Industry
- CDLR
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CDLR
- GLPG Health Care
- Exchange
- CDLR Nasdaq
- GLPG Nasdaq
- Market Cap
- CDLR 1.9B
- GLPG 1.9B
- IPO Year
- CDLR N/A
- GLPG 2005
- Fundamental
- Price
- CDLR $20.42
- GLPG $30.32
- Analyst Decision
- CDLR
- GLPG Sell
- Analyst Count
- CDLR 0
- GLPG 4
- Target Price
- CDLR N/A
- GLPG $25.33
- AVG Volume (30 Days)
- CDLR 91.8K
- GLPG 239.4K
- Earning Date
- CDLR 08-26-2025
- GLPG 07-23-2025
- Dividend Yield
- CDLR N/A
- GLPG N/A
- EPS Growth
- CDLR N/A
- GLPG N/A
- EPS
- CDLR 0.31
- GLPG N/A
- Revenue
- CDLR $319,011,025.00
- GLPG $311,493,731.00
- Revenue This Year
- CDLR $106.55
- GLPG $0.78
- Revenue Next Year
- CDLR $92.34
- GLPG N/A
- P/E Ratio
- CDLR $18.80
- GLPG N/A
- Revenue Growth
- CDLR 171.33
- GLPG 18.32
- 52 Week Low
- CDLR $17.37
- GLPG $22.36
- 52 Week High
- CDLR $28.75
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- CDLR 49.76
- GLPG 67.62
- Support Level
- CDLR $19.64
- GLPG $28.21
- Resistance Level
- CDLR $20.27
- GLPG $30.64
- Average True Range (ATR)
- CDLR 0.44
- GLPG 0.52
- MACD
- CDLR -0.08
- GLPG 0.23
- Stochastic Oscillator
- CDLR 49.87
- GLPG 91.29
About CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.